孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的疗效分析  

Analysis of therapeutic effect of montelukast sodium in treatment of asthma-chronic obstructive pulmonary disease

作　　者：刘宇智[1] 金宁[1] 王海斌[1] 

机构地区：[1]惠州市第六人民医院(南方医科大学附属惠州医院)呼吸科,广东惠州516211

出　　处：《临床肺科杂志》2017年第7期1293-1296,共4页Journal of Clinical Pulmonary Medicine

摘　　要：目的探究孟鲁司特钠治疗哮喘-慢阻肺重叠综合征的临床疗效。方法选取2014年1月至2016年2月于我院门诊或病房接受诊治的哮喘-慢阻肺重叠综合征患者64例,按照随机数字表法分为两组,每组32例,对照组患者给予常规治疗,观察组患者在对照组的基础上加用孟鲁司特钠,比较两组患者治疗前后呼吸困难指数分级、ACT评分、CAT评分、FEV_1%、FEV_1/FVC等指标。结果治疗前两组患者呼吸困难指数分级、ACT评分、CAT评分、FEV_1%、FEV_1/FVC比较无明显统计学差异(P>0.05),治疗后呼吸困难指数4级患者减少,0级患者增多,两组比较差异具有统计学意义(P<0.05);治疗后,两组患者ACT评分均较前提高,CAT评分下降,两组比较差异具有统计学意义(P<0.05);治疗后,两组患者FEV_1%、FEV_1/FVC均较前提高,治疗后两组FEV_1%、FEV_1/FVC比较,差异具有统计学意义(P<0.05)。结论孟鲁司特钠可明显改善哮喘-慢阻肺重叠综合征患者的哮喘和慢阻肺症状,提高肺功能水平,纠正呼吸困难,值得临床推广。Objective To explore the clinical effect of montelukast sodium in treatment of asthma-chronic obstructive pulmonary disease. Methods 64 COPD patients complicated with asthma were randomly divided into two groups,32 cases in each group. The control group was given normal therapy, and the observation group was given montelukast sodium on the basis of treatment of the control group. Their dyspnea index degree, ACT, CAT, FEV1% and FEV1 FVC were observed before and after treatment. Results There was no significant difference in dyspnea index grading,act score,cat score,FEV1 % or FEV1/FVC between the two groups before treatment （P〉0.05） . After treatment,the patients with dyspnea index 4 degree reduced, and 0 degree increased （ P 〈 0. 05 ）. The ACT scores increased in the two groups, and the CAT score decreased （P 〈 0. 05 ） . The levels of FEV1 % , FEV1/FVC improved, and the difference between the two groups was statistically significant （P 〈0. 05） . Conclusion Monte-lukast sodium can improve the symptoms of asthma and chronic obstructive pulmonary disease, which can improve pulmonary function and correct dyspnea. It is worth to widely clinical application.

关 键 词：孟鲁司特钠 哮喘-慢阻肺重叠综合征 呼吸困难指数 

分 类 号：R562.25[医药卫生—呼吸系统] R563.9[医药卫生—内科学]